Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics to Sequence 1,000 Genomes for NCI Pediatric Cancer Project

Premium

Complete Genomics will receive $8 million to sequence 500 tumor/normal pairs, or $8,000 per genome, as part of a National Cancer Institute initiative funded by the American Recovery and Reinvestment Act of 2009, the company said this week. The project aims to identify therapeutic targets in childhood cancers.

The contract follows on a previous phase of the project, during which the company sequenced 50 tumor/normal pairs from pediatric cancers, including acute lymphoblastic leukemia, acute myeloid leukemia, neuroblastoma, osteosarcoma, and Wilms tumor.

Complete Genomics originally mentioned the NCI contract during its second-quarter earnings call Aug. 4 (CSN 8/9/2011).

The project is part of NCI's Therapeutically Applicable Research to Generate Effective Treatments Initiative. For this, its second phase, Complete Genomics will focus on identifying somatic mutations associated with specific tumor types, and will submit the data to the TARGET database.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.